Idiopathic Stevens-Johnson syndrome and toxic epidermal necrolysis: Prevalence and patients' characteristics - 12/04/19
Funding sources: Between 2003 and 2007, the RegiSCAR study was funded by grants from the European Commission (QLRT-2002-01738), GIS-Institut des Maladies Rares, and INSERM (4CH09G) in France and by a consortium of pharmaceutical companies (Bayer Vital, Boehringer Ingelheim, GlaxoSmithKline, Merck Sharp and Dohme, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Servier, and Wyeth). The sponsors were not involved in the study design; collection, analysis, and interpretation of data; writing of the report; or decision to submit the article for publication. |
|
Conflicts of interest: None disclosed. |
|
Reprints not available from the authors. |
Vol 80 - N° 5
P. 1453-1455 - mai 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?